Fast Five Quiz: Refractory Myasthenia Gravis

Raghav Govindarajan, MD


October 13, 2021

Although approximately 80% of patients with MG are not able to achieve CSR, clinical factors and pathologic factors, such as thymic tumor stage, have not been shown to significantly impact a patient's path to CSR. These data suggest that the presence of thymoma is much more influential than other disease factors typically considered prognostic.

Results from a study by Baggi and colleagues demonstrate that the likelihood of CSR is lower in patients with thymoma than in those with involuted thymus histologic findings or thymic hyperplasia.

Learn more about the treatment of patients with MG.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.